TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01113398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102
Description: AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
Study: NCT02620462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor-based exercise training
Description: The device provides real-time visual feedback of joint movement during balance exercise
Study: NCT03787654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
Study: NCT00508521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: commercially available surface electrical stimulator

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard care as ordered by their physician and covered by their insurance company.
Study: NCT01029431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirQ Intubating Laryngeal Airway
Description: After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
Study: NCT03107403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web form
Description: The scale assessing the bereavement process is the one reported in Teissier 2010
Study: NCT01740063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F02 formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F04 formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03941912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EVRL
Description: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
Study: NCT03444649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Standard chemotherapy d1-d3 cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy d1-d7 cycle 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Standard chemotherapy d1-3 cycle 2
Study: NCT01169311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidopexy
Study: NCT03130439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
Study: NCT02418013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh cord blood(experimental group A)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen cord blood(experimental group B)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen plasma(experimental group C)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed.
Study: NCT02383108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG +DRV/r
Description: NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
Study: NCT00971711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
Study: NCT01178632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora
Description: 01 tablet Passiflora p.o., b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valeriana officinalis
Description: Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
Study: NCT04889131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program Immediately
Description: free 12 week yoga program, twice a week for 75 minutes each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-Listed Control
Description: assigned to take the Yoga Program in 12-weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitor
Description: Garmin VivoSmart activity monitor throughout study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Garmin VivoSmart activity monitor throughout study
Study: NCT04045886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Educational Modules (Videos)
Description: 5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Educational Modules (Videos)
Description: 5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
Study: NCT03814252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-TULSA
Description: The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)
Study: NCT00415090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Switch one of ARV drugs to Nevirapine
Study: NCT01468064

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous BMSCs transplantation
Description: The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transplantation
Description: The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: IV infusion of placebo
Description: IV infusion of saline plus 5% autologous serum.
Study: NCT02415556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Regular human insulin 40 IU daily over 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Regular human insulin 40 IU daily over 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal sterile saline 40 IU daily over 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal sterile saline 40 IU daily over 24 weeks
Study: NCT00492557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC + TIV
Description: Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
Study: NCT03081949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Selenite 200 µg/day for 3 months
Description: PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
Study: NCT02561949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YRI
Description: Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Income generating activity program
Description: Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Income generating activity program
Description: Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
Study: NCT03166449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neomune
Description: Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin® HP energy
Description: Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
Study: NCT03091010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
Study: NCT04973735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY-CovMab
Description: single IV infusion
Study: NCT04353674

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Patients randomized into this group will receive standard of care for COVID-19 infection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLEDD with a L-MOD
Description: Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
Study: NCT03702673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet A
Description: K-877 Controlled Release Tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet A
Description: K-877 Controlled Release Tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet A
Description: K-877 Controlled Release Tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet A
Description: K-877 Controlled Release Tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet B
Description: K-877 Controlled Release Tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet B
Description: K-877 Controlled Release Tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet B
Description: K-877 Controlled Release Tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet B
Description: K-877 Controlled Release Tablet B
Study: NCT00389220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent placement
Description: Coronary stent placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent placement
Description: Coronary stent placement
Study: NCT00266240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study: NCT01245036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antituberculous therapy along with steroids
Description: INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
Study: NCT00880087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia
Description: Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
Study: NCT03720769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-Step
Description: Guided self-help programme delivered through an app/website for the treatment of depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care as usual
Description: Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
Study: NCT02783430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One single perfusion during 40 minutes at the beginning of the inclusion
Study: NCT03702049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Community Health Worker TBI (RN/CHW TBI) program
Description: Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
Study: NCT03173170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Capsule
Study: NCT04413734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mono-chemotherapy
Description: Gemcitabine plus Cisplatin by intravenous infusion
Study: NCT03232255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse (IQP-OLP-101)
Description: Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
Study: NCT03702673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet E
Description: K-877 Controlled Release Tablet E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet E
Description: K-877 Controlled Release Tablet E
Study: NCT02731963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
Study: NCT03355209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 0.2 or 0.8 mg/kg/day
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 0.2 or 0.8 mg/kg/day
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered twice a day (BID) in equally divided doses.
Study: NCT02316158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based support
Description: Comparison between the efficacy between webb-based support and informational support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based support
Description: Comparison between the efficacy between webb-based support and informational support
Study: NCT00743509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
Study: NCT00427674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] mZINT injection and serial dynamic SPECT imaging
Description: Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.